| Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts | Ben Fidler | 04/13/18 | National |
| Bio Roundup: RNAi’s Big Day, CAR-T For Kids, Drugs From Fungi & More | Ben Fidler | 09/22/17 | National |
| Ex-Cubist CEO Bonney Emerges at Kaleido, Flagship’s Latest Microbiome Startup | Ben Fidler | 09/18/17 | Boston |
| Celgene Passes on Acetylon as Another Option-to-Buy Deal Flames Out | Ben Fidler | 08/08/16 | Boston |
| Gene Therapy Upstart Dimension Nabs $65M From “Crossover” Backers | Ben Fidler | 04/21/15 | Boston |
| Academia vs. BioPharma: Young Scientists Between A Rock and A Hard Place | Stewart Lyman | 04/06/15 | Seattle |
| Built for a Deal, Annovation Rewards Backers With Medicines Co. Buyout | Ben Fidler | 02/04/15 | Boston |
| Boston’s Life Science Disruptors: The Photos | Ben Fidler | 10/07/13 | Boston |
| San Diego Life Sciences News: Trius, Optimer, aTyr, Ligand, and More | Bruce V. Bigelow | 08/01/13 | San Diego |
| Cubist Says Adolor Deal Offers “Free Option on Billion-Dollar Program” | Arlene Weintraub | 10/26/11 | Boston |
| Alnylam Looks to ASCO as First “Bell-Ringing” for RNAi Resurgence | Arlene Weintraub | 05/26/11 | Boston |
| Optimer Antibiotic Gets Panel Nod, CareFusion Buys Vestara, Tracon Raises $16.5M, & More San Diego Life Sciences News | Bruce V. Bigelow | 04/07/11 | San Diego |
| Clinical Data Seeks to Challenge Lilly, Pfizer in Antidepressant Market | Ryan McBride | 05/11/10 | Boston |
| Kineta Acquires Multiple Sclerosis, Diabetes Drug Candidates to Test Unusual Biotech Strategy | Luke Timmerman | 07/08/09 | Seattle |
| Regulus Strikes Out On Its Own, J&J Seeks “Enlight”-enment, Synta Awaits Melanoma Data, & More Boston-Area Life Sciences News | Rebecca Zacks | 01/28/09 | Boston |
| Alnylam, Cubist Will Cooperate on RNAi Drug for Lung Infections | Wade Roush | 01/09/09 | Boston |
